Obicetrapib

Obicetrapib
Clinical data
Trade namesUbeslo
Other namesTA-8995; AMG-899
ATC code
  • None
Legal status
Legal status
  • EU: Rx-only
Identifiers
  • 4-[2-[[3,5-bis(trifluoromethyl)phenyl]methyl-[(2R,4S)-1-ethoxycarbonyl-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2H-quinolin-4-yl]amino]pyrimidin-5-yl]oxybutanoic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC32H31F9N4O5
Molar mass722.609 g·mol−1
3D model (JSmol)
  • CC[C@@H]1C[C@@H](C2=C(N1C(=O)OCC)C=CC(=C2)C(F)(F)F)N(CC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)C4=NC=C(C=N4)OCCCC(=O)O
  • InChI=1S/C32H31F9N4O5/c1-3-22-14-26(24-13-19(30(33,34)35)7-8-25(24)45(22)29(48)49-4-2)44(28-42-15-23(16-43-28)50-9-5-6-27(46)47)17-18-10-20(31(36,37)38)12-21(11-18)32(39,40)41/h7-8,10-13,15-16,22,26H,3-6,9,14,17H2,1-2H3,(H,46,47)/t22-,26+/m1/s1
  • Key:NRWORBQAOQVYBJ-GJZUVCINSA-N

Obicetrapib, sold under the brand name Ubeslo, is used for the treatment of dyslipidemia. It is a CETP inhibitor. Obicetrapib is a lipid-modifying agent that blocks a blood protein called CETP, thereby lowering the level of LDL cholesterol.

The most common side effects include hypertension, dizziness, headache, diarrhea, and abdominal pain.

Medical uses

Obicetrapib is indicated in adults with primary hypercholesterolemia (heterozygous familial and non familial) or mixed dyslipidemia, as an adjunct to diet in combination with a statin or statin with other lipid lowering therapies in people unable to reach low density lipoprotein cholesterol (LDL C) goals with the maximum tolerated dose of a statin; or alone or in combination with other lipid-lowering therapies in people who are statin intolerant, or for whom a statin is contraindicated.

History

Obicetrapib was initially developed by Amgen as AMG-899 and was abandoned in 2017. In 2020, Amgen licensed the drug to NewAmsterdam Pharma. In 2022, NewAmsterdam Pharma licensed the drug to Menarini Group.

In a clinical trial, as an add-on to statins, compared with placebo, it decreased concentrations of LDL-C (by up to 51%), apolipoprotein B (by up to 30%) and non-high-density lipoprotein cholesterol (non-HDL-C) (by up to 44%), and increased HDL-C concentration (by up to 165%).

Obicetrapib's ability to lower LDL cholesterol (“bad” cholesterol) compared with placebo was observed in two 52-week, randomized, double-blind, placebo-controlled studies in adults with high cholesterol and/or mixed dyslipidemia who were already receiving the maximum tolerated cholesterol-lowering treatment.

Society and culture

Obicetrapib was authorized for medical use in the European Union in September 2026.

Names

Obicetrapib is the International nonproprietary name.

Obicetrapib is sold under the brand name Ubeslo.